<code id='EBDA702BFB'></code><style id='EBDA702BFB'></style>
    • <acronym id='EBDA702BFB'></acronym>
      <center id='EBDA702BFB'><center id='EBDA702BFB'><tfoot id='EBDA702BFB'></tfoot></center><abbr id='EBDA702BFB'><dir id='EBDA702BFB'><tfoot id='EBDA702BFB'></tfoot><noframes id='EBDA702BFB'>

    • <optgroup id='EBDA702BFB'><strike id='EBDA702BFB'><sup id='EBDA702BFB'></sup></strike><code id='EBDA702BFB'></code></optgroup>
        1. <b id='EBDA702BFB'><label id='EBDA702BFB'><select id='EBDA702BFB'><dt id='EBDA702BFB'><span id='EBDA702BFB'></span></dt></select></label></b><u id='EBDA702BFB'></u>
          <i id='EBDA702BFB'><strike id='EBDA702BFB'><tt id='EBDA702BFB'><pre id='EBDA702BFB'></pre></tt></strike></i>

          knowledge

          knowledge

          author:fashion    Page View:94
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          FDA rejects Alnylam's heart disease treatment over insufficient data
          FDA rejects Alnylam's heart disease treatment over insufficient data

          KristofferTripplaar/SipaUSA/APTheFoodandDrugAdministrationrejectedanAlnylamPharmaceuticals’therapyfo

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Eli Lilly buys Point Biopharma in radiopharmaceuticals play

          DarronCummings/APAcouplebillionhere,acouplebillionthere,andprettysoonEliLillyhopesitwillbetalkingabo